KR20140131049A - Pharmaceutical composition for preventing or treating diabetes comprising extract of Dioscoreae Rhizoma and Calystegia japonica as an active ingradient - Google Patents

Abstract

The present invention relates to a pharmaceutical composition containing a Dioscoreae rhizoma extract and a Calystegia japonica extract as active ingredients for preventing and treating diabetes. More specifically, the α-glucosidase activity inhibiting effect is significantly higher when the Dioscoreae rhizoma extract and the Calystegia japonica extract are mixed than when the extracts are used alone, and thus the mixture can be useful as a pharmaceutical composition for preventing and treating diabetes or a health food composition for preventing and treating diabetes.

Description

[0001] The present invention relates to a pharmaceutical composition for preventing or reducing diabetes mellitus comprising Dioscoreae Rhizoma and Calystegia japonica as an active ingradient,

The present invention relates to a pharmaceutical composition for preventing and treating diabetes, comprising Dioscoreae Rhizoma and Calystegia japonica extract as an active ingredient.

Diabetes mellitus, a chronic metabolic disease, is a disease caused by deficiency of insulin in the body or insufficient response of cells to insulin, resulting in an increase in the blood glucose level due to the inability to control the blood glucose concentration. According to the American Diabetes Statistics Association, when the fasting blood glucose level is 140 mg / dl or more and 75 g of glucose is orally administered, blood glucose is measured at intervals of more than 2 hours at intervals of 30 minutes, when the blood glucose level is more than 200 mg / dl or glucose intolerance To diagnose diabetes.

According to the Korean Diabetes Research Report of the Korean Diabetes Society in 2012, one out of every 10 Koreans over the age of 30 is diabetic and 2 out of 10 have an impaired fasting glucose level, a potential diabetes stage, The prevalence of diabetes increased from 8.6% in 2001 to 10.1% in 2010, suggesting that the prevalence of diabetes rapidly increases, suggesting that the management of diabetes is urgent to promote public health.

Common symptoms of diabetes, a chronic metabolic disease, are known to be thirst, weight loss, fatigue, limp and pain, swelling of the legs, pruritus (pruritus), eye irritation or dizziness. Diabetes is known to be a more serious complication than the primary pain caused by the disease. Common complications caused by diabetes include diabetic retinopathy, eye diseases such as cataract, diabetic neuropathy (reduction of foot blood flow, foot ulceration, paralysis, (Diabetic nephropathy), and hypertension, and more than 50% of diabetic patients die due to complications or due to complications, such as diabetes mellitus, diabetes mellitus, etc.), capillary vascular disorders and cardiovascular diseases (increased risk of heart disease and stroke) It has been reported to suffer serious discomfort in everyday life.

Diabetes mellitus can be classified into insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) according to the etiology of the disease. And treatment methods are different.

Insulin-dependent type 1 diabetes is a disease caused by the breakdown of pancreatic beta cells or the development of insulin-producing disorder due to gene expression abnormality. It is treated continuously by feeding insulin into the body and is often caused by genetic causes. Possible features.

Type 2 diabetes is a type of non-insulin dependent diabetes mellitus that produces normal or over-secreted insulin in the body, but insulin resistance causes insulin's ability to regulate metabolism. In Koreans, type 2 diabetes accounts for 90% of all diabetes . Type 2 diabetes mellitus is a type of adult diabetes mellitus that is closely related to obesity. It is known to occur mainly after the age of 40, but the age of onset is gradually decreasing in recent years.

Type 1 diabetes and type 2 diabetes differ not only in the timing of the onset and the nature of the disease, but also in the severity of the disease and in the way they are treated. Insulin-dependent diabetes mellitus (Type 1 diabetes) requires repeated, continuous insulin injections because of insufficient secretion of insulin.

In the treatment of non-insulin dependent diabetes mellitus (type 2 diabetes), an oral hypoglycemic agent is used to control blood sugar. Sulfonylureas promote insulin secretion, but do not affect blood, gastrointestinal, cardiovascular, The biguanides system inhibits glucose production in the liver, but has side effects in the gastrointestinal tract, and α-glucosidase inhibitors such as acarbose and voglibose are continuously The disaccharide is inhibited by the action of digestive enzymes and is transported to the large intestine and degraded by the bacteria present in the colon, resulting in side effects related to excretion of gas, diarrhea and constipation (Ron et al. , 2002).

Recently, studies on the development and treatment of type 2 diabetes mellitus in which side effects are minimized by using the inhibitory activity of? -Glucosidase of a natural substance-derived substance with a low side effect have been actively studied. α-glucosidase is a kind of digestive enzyme that ultimately converts saccharides degraded by α-amylase to monosaccharides and is a main factor for raising postprandial glucose concentration in the body (Kim et al. al., 2006). Inhibition of the activity of alpha -glucosidase slows down the hydrolysis and absorption of carbohydrates, which limits the postprandial glucose concentration and is useful for the treatment of diseases related to the absorption of carbohydrates such as type 2 diabetes (Baron , 1998).

Dioscoreae Rhizoma is the root of the root of the lily-of-the-neck or the root-relative plant. It is a perennial perennial plant native to Korea. It has 9 genera of 1st genus in Korea. It grows domestically ( Dioscorea batatas Dense.) And yam ( D. japonica Thunb.).

In addition, the effects of Ganoderma lucidum are not known (Hikono et al., 1986), and the effect of cholesterol lowering in blood (Chen et al., 2003), as well as enhancement of gastrointestinal function (Jeon et al., 2006; Wang et al., 2007) (Yang et al., 2009) and anti-obesity effect (Kwong et al., 2003) have been reported. In addition, in the oriental medicine, it has been used for the treatment of diarrhea, food shortage, seawater, soot, oil well,

However, it is necessary to supplement the effect of blood glucose lowering effect by using it together with other raw materials because it is slightly insufficient to exhibit blood glucose lowering effect alone.

Calyx ( Calystegia japonica ) is a perennial herbaceous herbaceous perennial plant, which is distributed in Korea, China and Japan. Its rootstock and young leaves are edible. In Korea, there are plants related to the symmetry of the meiosis, such as Aegisome, Sunmei, Big, White, and White. In one room, it is called "Guo Guan" or "Shenhua", and the taste is sweet and the quality is classified as cold medicine. The main efficacy is known as 清热, consonant, 降压. In clinical practice, it is said that the blood pressure is lowered by consonant, and it is diuretic. The rootstock is the treatment of indigestion, (Stomach), is known to be used to promote the fusion of fractures.

It is a perennial vine plant, and it has the advantage of easy growing and propagation because it grows and breeds without any distinction in the growing place. It is a material used for edible purposes because of its toxicity. The value of use as a material for medicines and functional foods is not well known.

Accordingly, the inventors of the present invention have found that, when researching natural materials having excellent blood glucose lowering effect and few side effects, the use of Acacia japonica or Saccharomyces cerevisiae significantly inhibits the α-glucosidase activity, and the effect thereof is enhanced by the commercially available α-glucosidase inhibitor acarbose The present invention has been completed.

The present invention relates to a pharmaceutical composition for preventing and treating diabetes, comprising Dioscoreae Rhizoma and Calystegia japonica extract as an active ingredient.

The present invention relates to a pharmaceutical composition for preventing and treating diabetes, comprising Dioscoreae Rhizoma and Calystegia japonica extract as an active ingredient.

The present invention also provides a health food for prevention and improvement of diabetes mellitus containing as an active ingredient an extract of Matsumitake and a flower of Mycobacterium tuberosum.

The present invention provides a pharmaceutical composition for prevention and treatment of diabetes mellitus, which comprises: (1) a composition for prevention and treatment of diabetes mellitus, (2) a composition for preventing and treating diabetes mellitus, , And an active ingredient of a health food composition.

Fig. 1 is a chart for confirming the inhibitory activity of? -Glucosidase of acarbose, Acanthopanax acanthopanacum extract and Mycobacterium tuberculosis extract.
^{1) The} inhibitory activity was compared by T-test at the 5% significance level ( p <0.001)
Fig. 2 is a graph showing the inhibitory activity of? -Glucosidase by a combination of an Acanthopanacum mellifera extract and a Mycobacterium tuberculosis extract.
^{1) The} inhibitory activity was compared by T-test at the 5% significance level ( p <0.001)
FIG. 3 is a graph showing the comparison between the predicted α-glucosidase inhibitory activity and the measured value by the combination of the Acanthopanac apparatuses extract and the Japanese Mycorrhizae extract.
^{2) The} inhibitory activity was compared by T-test at the 5% significance level ( p <0.001)

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for the prevention and treatment of diabetes comprising Dioscoreae Rhizoma and Calystegia japonica extract as an active ingredient.

The scallop and mycelia extract preferably have a blood glucose lowering effect, but are not limited thereto.

Preferably, the mixture of scallop and mycelium extracts is prepared by a process comprising the following steps:

1) Extracting each of the Acacia var.

2) filtering the extract of each of the Acanthopanax senticosus and Mycobacterium tuberculosis of Step 1);

3) concentrating each of the filtered extracts obtained in step 2) under reduced pressure, and drying the extract to prepare a scallop and flower extract; And

4) Mixing the scallop and mycelium extracts of step 3).

In the above method, the liquorice and the flower of step 1) can be used without limitation such as cultivated or commercially available. It is most preferable to use the roots of roots, branches, stems, leaves, petals and buds of maize or its copper-free root-associated plants, or roots of roots of the roots of the same plants. It is most preferred to use the rootstocks of the plants of the plants of the plants of the mycelia or the plants of the myosinophyte-associated plants, although the plants may be any of leaves, rootstocks, branches, stems, petals and buds of the plants.

In the above method, it is preferable to use water, an alcohol or a mixture thereof in the extraction solvent of the step 1). As the alcohol, C ₁ to C ₂ lower alcohols are preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. It is preferable that the extraction solvent is added by 1 to 10 times the amount of the dried mackerel and rice flour, and it is more preferable that the extraction solvent is added by 2 to 3 times. The extraction temperature is preferably 20 占 폚 to 100 占 폚, and most preferably room temperature, but is not limited thereto. The extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. In addition, the number of times of extraction is preferably 1 to 5 times, more preferably 3 to 4 times, more preferably 3 times, but not always limited thereto.

In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. Drying is preferably, but not exclusively, reduced-pressure drying, vacuum drying, boiling drying, spray drying, or lyophilization.

The extracts of Saccharomyces cerevisiae and Mycobacterium tuberosum can be prepared by mixing the extracts of Saccharomyces cerevisiae and Mycobacterium tuberculosis, or extracting Saccharomyces cerevisiae and Saccharomyces cerevisiae after mixing them. However, the present invention is not limited thereto.

The saccharose and mycelium extracts are preferably mixed at a weight ratio of 6: 1 to 1: 1, more preferably 3: 1 to 1: 1, and most preferably 1: 1 Do.

In addition, the scallop and mycelia extracts of the present invention are preferably prepared by the following steps, but are not limited thereto:

1) heating and extracting each of the Acanthopanax senticosus and Mycenae species with an extraction solvent;

2) separating each of the extracts of step 1) by filtration;

3) concentrating each of the filtrates in step 2) to obtain a soft X-ray;

4) drying each concentrate of step 3) to obtain a dry extract; And

5) mixing the respective soft-toned extracts or dry extracts of step 4).

In the above method, the liquorice and the flower of step 1) can be used without limitation such as cultivated or commercially available. It is most preferable to use the roots of roots, stems, leaves, petals and buds of maize or its copper-free root-associated plants, but it is most preferable to use roots of roots of roots of the same or similar plants. It is most preferable to use the roots, leaves, stems, petals, and buds of the Japanese cabbage, or the roots of the Chinese cabbage or its copper-free root associated plants.

In the above method, the extraction solvent of step 1) is preferably, but not limited to, water, ethanol or a mixture thereof.

In the above method, the extraction temperature of the crude extract of step 1) is preferably 50 to 70 ° C, more preferably 55 to 65 ° C, and most preferably 60 ° C. The extraction time is preferably 2 to 4 hours, more preferably 2 to 3 hours, most preferably 3 hours, but not always limited thereto.

The extraction temperature of the step (1) of the above method is preferably 50 to 90 ° C, more preferably 70 ° C, and most preferably 60 ° C. The extraction time is preferably 1 to 9 hours, more preferably 3 to 6 hours, most preferably 6 hours, but is not limited thereto.

In the above method, it is most preferable that the soft X-ray of step 3) is concentrated under reduced pressure, but it is not limited thereto.

In the above method, the drying extract of step 4) is most preferably but not limited to spray drying the concentrate of step 3).

In a specific example of the present invention, the inventors of the present invention compared α-glucosidase inhibitory activity using acarbose as a positive control in order to confirm the hypoglycemic effect of scallop and mycelium extracts. As a result, The extracts of each of the extracts of Acanthopanax senticosus and Mycobacterium tuberosum showed excellent α-glucosidase inhibitory activity at the same concentration (1.2 mg) as commercially available acarbose (see Table 1 and FIG. 1).

Further, the inventors of the present invention found that the inhibitory activity of? -Glucosidase was significantly increased when the extract was used alone (see FIG. 2).

In addition, the α-glucosidase inhibitory activity of the present invention and the extract of Mycobacterium tuber of the present invention are more remarkable than those predicted by using the colby method, so that the mixture of the extracts can be used as a composition for the prevention and treatment of diabetes (See Table 2 and Fig. 3).

Therefore, the extract of Saccharomyces japonica and Saccharomyces cerevisiae of the present invention remarkably inhibits? -Glucosidase when the extract alone is used or compared with existing commercial acarbose, and thus it is usefully used as an effective ingredient of a composition for the prevention and treatment of diabetes .

The composition containing the mixture of the Acacia mulberry extract and the Mycobacterium tuberosum extract of the present invention may further contain one or more active ingredients which exhibit the same or similar functions in addition to the above components.

The composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose Starch glycolate, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, calcium stearate, , White sugar, dextrose, sorbitol and talc. The pharmaceutically acceptable additives according to the present invention are preferably included in the composition in an amount of 0.1 to 90 parts by weight, but are not limited thereto.

That is, the composition of the present invention can be administered in various formulations of oral and parenteral administration at the time of actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, . &Lt; / RTI &gt; Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, Sucrose, Lactose, Gelatin, or the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.

The composition of the present invention may be administered orally or parenterally in accordance with the intended method, and may be administered orally, parenterally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly, . The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.

The dosage unit may contain, for example, 1, 2, 3 or 4 times the individual dose or may contain 1/2, 1/3 or 1/4 times the dose. The individual dosages specifically include amounts in which the active drug is administered in a single dose, which usually corresponds to the full, half, one-third, or one-fourth of the daily dose. The effective dose of the composition of the present invention may be 0.0001 to 10 g / kg, more specifically 0.001 to 1 g / kg, and may be administered 1 to 6 times a day. However, the dosage may not be limited in any way because it may be increased or decreased depending on route of administration, severity of disease, sex, weight, age, and the like.

The present invention also provides a health food for diabetes prevention and improvement comprising an extract of Matsumyu and a flower of Aspergillus as an active ingredient.

Preferably, the mixture of scallop and mycelium extracts is prepared by a process comprising the following steps:

1) Extracting each of the Acacia var.

2) filtering the extract of each of the Acanthopanax senticosus and Mycobacterium tuberculosis of Step 1);

3) concentrating each of the filtered extracts obtained in step 2) under reduced pressure, and drying the extract to prepare a scallop and flower extract; And

4) Mixing the scallop and mycelium extracts of step 3).

In the above method, the liquorice and the flower of step 1) can be used without limitation such as cultivated or commercially available. It is most preferable to use the roots of roots, stems, leaves, petals and buds of maize or its copper-free root-associated plants, but it is most preferable to use roots of roots of roots of the same or similar plants. It is also possible to use any of the rootstocks, the stem, the leaves, the petals and the buds of the plants of the Mycobacterium tuberosum or the mycorrhizae associated plants thereof, but it is most preferable to use the rootstocks of the mycorrhizae or the mycobacteria.

In the above method, it is preferable to use water, an alcohol or a mixture thereof in the extraction solvent of the step 1). As the alcohol, C ₁ to C ₂ lower alcohols are preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. It is preferable that the extraction solvent is added by 1 to 10 times the amount of the dried mackerel and rice flour, and it is more preferable that the extraction solvent is added by 2 to 3 times. The extraction temperature is preferably 20 占 폚 to 100 占 폚, and most preferably room temperature, but is not limited thereto. The extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. In addition, the number of times of extraction is preferably 1 to 5 times, more preferably 3 to 4 times, more preferably 3 times, but not always limited thereto.

In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. Drying is preferably, but not exclusively, reduced-pressure drying, vacuum drying, boiling drying, spray drying, or lyophilization.

The extracts of Saccharomyces cerevisiae and Mycobacterium tuberosum can be prepared by mixing and preparing the respective extracts, or mixing the Saccharomyces cerevisiae and Mycobacterium saccharum, and then extracting them, but the present invention is not limited thereto.

The saccharose and mycelium extracts are preferably mixed at a weight ratio of 5: 1 to 1: 1, more preferably 3: 1 to 1: 1, and most preferably 1: 1 Do.

In addition, the scallop and mycelia extracts of the present invention are preferably prepared by the following steps, but are not limited thereto:

1) heating and extracting each of the Acanthopanax senticosus and Mycenae species with an extraction solvent;

2) separating each of the extracts of step 1) by filtration;

3) concentrating each of the filtrates in step 2) to obtain a soft X-ray;

4) drying each concentrate of step 3) to obtain a dry extract; And

5) mixing the respective soft-toned extracts or dry extracts of step 4).

In the above method, the liquorice and the flower of step 1) can be used without limitation such as cultivated or commercially available. It is most preferable to use the roots of roots, stems, leaves, petals and buds of maize or its copper-free root-associated plants, but it is most preferable to use roots of roots of roots of the same or similar plants. In addition, it is possible to use any of the rootstocks, the stem, the leaves, the petals and the petal ducks of the plants of the Mycenae or the mycorrhizae associated plants thereof, but it is most preferable to use the rootstocks of the mycorrhizae plant.

In this method, the extraction solvent of step 1) is preferably, but not limited to, water, ethanol, alcohol, or a mixture thereof. According to an embodiment of the present invention, it is preferable that the mixed solvent is used in an amount of 60 to 90% alcohol, and most preferably, 80% alcohol is used.

In the above method, the extraction temperature of the crude extract of step 1) is preferably 50 to 70 ° C, more preferably 55 to 65 ° C, and most preferably 60 ° C. The extraction time is preferably 2 to 4 hours, more preferably 2 to 3 hours, most preferably 3 hours, but is not limited thereto.

In the above method, the extraction temperature of the step (1) is preferably 50 to 90 ° C, more preferably 70 ° C, and most preferably 60 ° C. The extraction time is preferably 1 to 9 hours, more preferably 3 to 6 hours, most preferably 6 hours, but is not limited thereto.

In the above method, it is most preferable that the soft X-ray of step 3) is concentrated under reduced pressure, but it is not limited thereto.

In the above method, the dry extract in step 4) is most preferably spray-dried, but not limited thereto.

Therefore, the extract of Saccharomyces japonica and Saccharomyces cerevisiae of the present invention remarkably inhibits -glucosidase compared to the commercially available acabos or when used alone as an effective ingredient of a composition for the prevention and treatment of diabetes have.

The health food of the present invention can be used as it is or in combination with other food or food ingredients, and can be suitably used according to conventional methods.

There is no particular limitation on the kind of the health food. Examples of the food to which the safflower and the flowerpotted mixed extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, Tea, a drink, an alcoholic beverage, and a vitamin complex, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 of the composition of the present invention.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples.

However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples, Experimental Examples and Preparation Examples.

&Lt; Example 1 > Production of Acidic Drug Extract

The ethanolic ethanol extract used in the present invention was prepared.

Specifically, 10 kg of the acid 10 kg which was confirmed by Dong-Hee Pharmaceutical Co., Ltd. was purchased from Shin-Kang Pharmaceutical Co., Ltd., 501 Dongjin-ri, North Dongnam, Gyeongbuk Province and put into the extraction tank, and 80% And the mixture was refluxed and cooled at 60 ° C for 3 hours. In the extraction process, the extract was filtered with a paper filter paper, 80% ethanol was added to the filtrate, and the extract was extracted at 60 for 3 hours. The extract was filtered using a paper filter paper. The filtrate was concentrated under reduced pressure at 50 or less and used as a soft X-ray extract, spray-dried and used as a dry extract.

&Lt; Example 2 >

The ethanol extract of the mycelia of rice flour used in the present invention was prepared.

Specifically, the collected flower flies from Mungyeong-city, Kyungbuk Province were washed, dried and pulverized. Then, 10 kg was added to the extraction tank, and 80 L of 80% alcohol was added for extraction at 60 for 3 hours. In the extraction process, 400 extracts were used for filtration. The filtrate was filtered through 400 mesh and then concentrated under reduced pressure to a Brix of 45 or lower. The concentrate was concentrated to 89 Brix and used as a soft X-ray, spray-dried and used as a dry X-ray.

&Lt; Example 3 > Preparation of composition for lowering blood glucose level

Compositions for lowering blood glucose levels were prepared by mixing the mash extract and mycelia extract prepared by the methods of Example 1 and Example 2 above.

Specifically, 1.2 mg of dry extracts of each of the above-mentioned scallions and mycelia extracts were used, or they were prepared so as to have a weight ratio of 6: 2 to 6: 6, respectively, and 1.2 mg as a total dry extract was used. In order to homogenize the mixture, the extract of Acanthopanax senticosus and the extract of Mycobacterium tuberosum were added in a quantity and homogeneously homogenized with a homogenizer or a magnetic stirrer (about 30 to 60 rpm).

<Experimental Example 1> Comparison of α-glucosidase inhibitory activity of Acanthopanax senticosus

In order to confirm the hypoglycemic effect of the extract of Saccharomyces cerevisiae and Mycelium extract prepared by the methods of Example 1 and Example 2, α-glucosidase inhibitory activity was confirmed.

Specifically, α-glucosidase (G5003, sigma) was diluted to 0.35 units with 100 mM salt buffer (pH 7.02) and used as a substrate, ρ-NPG [4-nitrophenyl-D- 4-nitrophenyl-D-glucopyranoside, N1377, Sigma] was prepared at 1.5 mM using PBS (pH 7.4). Thereafter, 100 μl of 0.35 unit / mL of α-glucosidase was added to 50 μl of a sample obtained by dissolving 1.2 mg of dried extract in 2% DMSO, followed by reaction at 37 ° C. for 5 minutes. Then, 1.5 mM ρ-NPG 50 Was added and reacted at 37 ° C for 20 minutes. After the reaction was completed by adding 1 mL of 1 M Na ₂ CO ₃ , α-glucosidase was reacted with the substrate to form ρ-nitrophenol (ρ-nitrophenol) was measured at 405 nm to evaluate the inhibitory activity of α-glucosidase. All samples were concentrated under reduced pressure and then diluted with 2% DMSO. As a negative control, 2% DMSO solvent was used as a sample solvent and acarbose was used as a positive control. The α-glucosidase inhibitory activity of the sample and the positive control group was determined using the following Equation (1).

       A: absorbance of the sample (405 nm),

B: absorbance (405 nm) of the treatment with α-glucosidase and buffer solution instead of ρ-NPG, and

C: Absorbance of the 2% DMSO treatment (405 nm).

As a result, as shown in Fig. 1, it was confirmed that the acid mackerel and mycelia extract inhibited the α-glucosidase inhibitory activity, and the acid mackerel and the mungbean flower extract showed more excellent activity at the same concentration as that of commercially available acabos (1.2 mg) (Fig. 1).

Experimental Example 2 Confirmation of α-glucosidase Inhibitory Activity by Mixing Ratio of Acanthopanum sp.

Glucosidase inhibitory activity according to the method of Experimental Example 1 according to the extracts of Acanthopanax senticosus, Mycorrhiza extract and their mixture ratio (6: 2, 6: 3, 6: 4, 6: 5, 6: Respectively.

Specifically, in order to confirm the remarkable effect of each combination, an estimate of each combination was obtained using the results of Table 1 using the Colby method of Equation (2) below, and the predicted value derived by the Colby method And the measured values were compared (Table 2).

       E: Expected,

A: α-glucosidase inhibitory activity of the extract of Acanthopanax senticosus, and

B: α-glucosidase inhibitory activity of the extract of the Japanese mackerel.

Amount of dried extract (mg / 50 μl) ? -glucosidase inhibitory activity (%)

Light

0.90 49.6 ± 0.70 0.80 47.1 ± 0.62 0.72 45.1 ± 0.55 0.65 43.5 ± 0.50 0.60 42.1 ± 0.45

convolvulus

0.30 22.1 ± 1.08 0.40 32.5 ± 0.61 0.48 40.9 ± 0.24 0.55 47.6 ± 0.11 0.60 53.4 ± 0.34

Extract ¹⁾ ? -glucosidase inhibitory activity (%) Measures Expected ²⁾ Acabos 52.7 ± 0.52 ^e3) - Light 57.7 ± 0.37 ^d - convolvulus 78.6 ± 2.43 ^c - Sacred flower: Mycelium = 6: 2 73.7 ± 1.03 ^c 60.7 ± 0.31 Sacred flower: Mycelium = 6: 3 84.9 ± 0.75 ^b 64.3 ± 0.23 Saccharomyces: Saccharomyces cerevisiae = 6: 4 85.1 ± 1.71 ^b 67.5 ± 0.22 Sacred flower: Mycelium = 6: 5 87.7 ± 0.69 ^b 70.4 ± 0.28 Sacred flower: Mycelium = 6: 6 100.0 + 0.40 ^a 73.0 + - 0.35

¹⁾ All extracts were adjusted to a concentration of 1.2mg / 50μl.

²⁾ Estimates using colby assay.

³⁾ Compared with Duncan's multiple range test at 5% significance level ( p <0.001).

As a result, as shown in Fig. 2, it was confirmed that a synergistic effect was more remarkable than the case of using each of the extracts of Asakusa and Myzaniki (Fig. 2). As shown in FIG. 3, when the extracts of Acanthopanax senticosus and Myzanovirus extracts were mixed at a ratio of 6: 2 to 6: 6 and 1.2 mg / 50 μl as a total extractive extract, the α-glucosidase- (Table 2, Fig. 3). &Lt; tb &gt; &lt; TABLE &gt;

In the present invention, the extract prepared by combining 0.6 mg of the crude extract with 0.6 mg of the extract of the Japanese mackerel, 0.6: 1, completely inhibited the activity of? -Glucosidase under the above conditions. Therefore, it was confirmed that the use of the combination of the scallops and the saccharomyces at a ratio of 1: 1 is more effective than the existing α-glucosidase inhibitor acabos and shows a significant effect than that of the scallops or the saccharin alone (Fig. 3).

&Lt; Preparation Example 1 > Preparation of pharmaceutical preparations

<1-1> Preparation of powder

A mixture of the Acanthopanax senticosus and Myzanarium Extract of the present invention 2 g

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

<1-2> Preparation of tablets

A mixture 100 of the Acanthopanax senticosus and Myzanarium Extract of the present invention

Corn starch 100

100 per 100

Magnesium stearate 2

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 1-3 > Preparation of capsules

A mixture 100 of the Acanthopanax senticosus and Myzanarium Extract of the present invention

Corn starch 100

100 per 100

Magnesium stearate 2

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

&Lt; 1-4 >

1 g &lt; RTI ID = 0.0 &gt;

Lactose 1.5 g

Glycerin 1 g

0.5 g of xylitol

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

<1-5> Preparation of granules

A mixture of the Acanthopanax senticosus and Myzanarium Extract of the present invention 150

Soybean extract 50

Glucose 200

Starch 600

After mixing the above components, 100% of 30% ethanol was added and the mixture was dried at 60 ° C to form granules, which were then filled in a capsule.

&Lt; Preparation Example 2 > Preparation of health food

<2-1> Production of flour food

0.5-5.0 parts by weight of a mixture of the Acacia japonica extract and the Mythospora japonica extract of the present invention was added to wheat flour and the mixture was used to prepare bread, cake, cookies, crackers and noodles.

<2-2> Production of soups and gravies

0.1-5.0 parts by weight of a mixture of the Acanthopanax senticosus extract and Mycobacterium tuberosum L. extract of the present invention was added to soups and juices to prepare health promotion meat products, noodle soups and juices.

<2-3> Preparation of ground beef

10 parts by weight of a mixture of the Acacia japonica L. and the Mythospora japonica extract of the present invention was added to ground beef to prepare a ground beef for health promotion.

<2-4> Manufacture of dairy products

5 to 10 parts by weight of a mixture of an Acacia japonica and a Mycobacterium tuberculosis extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

&Lt; 2-5 >

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The mixture of the scallions and the extract of the Japanese mackerel of the present invention was concentrated under reduced pressure in a vacuum concentrator, sprayed and dried with a hot-air drier, and the dried material was pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.

The grains, seeds, and the mixture of the extract of the present invention and the mash extract of the present invention were prepared in the following proportions.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

A mixture (3 parts by weight) of the Acanthopanax senticosus extract and the Japanese Myosini extract of the present invention,

(0.5 part by weight),

(0.5 parts by weight)

&Lt; Preparation Example 3 > Preparation of beverage

<3-1> Production of health drinks

5 g of a mixture of a mixture of liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75% After sterilization, they were packaged in small containers such as glass bottles and plastic bottles.

<3-2> Preparation of vegetable juice

A vegetable juice was prepared by adding 5 g of the mixture of the Acacia japonica extract and the Mythospora japonica extract of the present invention to 1,000 tomato juice or carrot juice.

<3-3> Production of fruit juice

A fruit juice was prepared by adding 1 g of a mixture of an Acacia japonica extract and a Mycobacterium tuberosum extract of the present invention to 1,000 apple or grape juice.

Claims (10)

A pharmaceutical composition for the prevention and treatment of diabetes comprising Dioscoreae Rhizoma and Calystegia japonica extract as active ingredients.
[Claim 2] The pharmaceutical composition according to claim 1, wherein the extract is prepared by mixing scallions and Japanese cabbage at a weight ratio of 3: 1 to 1: 1.
The pharmaceutical composition according to claim 1, wherein the extract is extracted with water, alcohol or a mixture thereof.
4. The pharmaceutical composition according to claim 3, wherein the alcohol is a C1 to C2 lower alcohol.
5. The pharmaceutical composition according to claim 4, wherein the lower alcohol is ethanol or methanol.
[Claim 2] The pharmaceutical composition according to claim 1, wherein the scab and extracts of Myxosus japonica exhibit a hypoglycemic effect.
A health food for prevention and improvement of diabetes containing an active ingredient of liquorice extract and mycorrhizae extract.
[Claim 7] The pharmaceutical composition according to claim 7, wherein the extract is a mixture of scallions and Japanese cabbage at a weight ratio of 3: 1 to 1: 1.
8. The health food according to claim 7, wherein the extract is extracted with water, alcohol or a mixture thereof.
[Claim 7] The health food according to claim 7, wherein the safflower seeds and the Japanese cabbage extract have a hypoglycemic effect.

Images